Last reviewed · How we verify
RAY1216
RAY1216 is an investigational therapeutic targeting a specific molecular pathway relevant to its indication, currently in phase 3 clinical development.
At a glance
| Generic name | RAY1216 |
|---|---|
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
RAY1216 is being developed by Guangdong Raynovent Biotech Co., Ltd as a phase 3 candidate. Limited public information is available regarding its precise mechanism of action, molecular target, or therapeutic indication at this stage of development.
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants (PHASE1)
- Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China (PHASE1)
- Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin (PHASE1)
- Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease (PHASE1)
- Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment (PHASE1)
- Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19 (PHASE3)
- The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAY1216 CI brief — competitive landscape report
- RAY1216 updates RSS · CI watch RSS
- Guangdong Raynovent Biotech Co., Ltd portfolio CI